NP与MVP方案治疗晚期NSCLC的对照研究

目的通过随机对照研究,比较NP与MVP方案治疗晚期非小细胞肺癌(NSCLC)的疗效,并观察其毒副作用.方法共65例晚期NSCLC患者随机入组,治疗组30例应用NP方案(NVB+DDP),对照组35例应用MVP方案(MMC+VDS+DDP).每病例至少化疗2疗程.疗效及毒副作用评价均按WHO标准进行.结果治疗组CR3例,PR11例,总有效率46.6%,对照组CR1例,PR12例,总有效率37.1%.治疗组总有效率要高于对照组,但无统计学差异(P＞0.05).治疗组中位生存期8.5月,而对照组7.6月,两组无差异(P＞0.05).两组病例主要的毒副作用是骨髓抑制、消化道反应及静脉炎.结论NP方案可以在NSCLC治疗中作为一线方案逐步应用,并进一步研究.

A RANDOMIZED TRIAL OF NAVELBINE PLUS CISPLATIN VERSUS MITOMYCIN-C PLUS VINDESINE PLUS CISPLATIN IN TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

Objective:To compare the response and side effects of the regimen NP (NVB DDP) with MVP (MMC VDS DDP) in treatment of advanced non same cell lung cancer (NSCLC).Methods:A total of 65 cases with advanced NSCLC were randomly divided into trial group and the control group,repectively,received NP regimen or MVP regimen.Each patient received at least 2 cycles chemotherapy.The response and toxic effects were evaluated according to WHO criteria.Rusults:Overall response rate was 46.6 %(14/30) in the NP group,overall response rate was 37.1 %(13/35) in the MVP group,but the difference between the groups did not reach statistical significance ( P >0.05).The median survival time was 8.5 months in NP group,and 7.6 months in MVP group ( P >0.05).Myelotoxicity,nausea/vomiting and phlebitis was the most frequently observed toxic effects in the two groups.Conclusion:The results of this study demonstrated that NP regimen had a better efficacy than MVP regimen for NSCLC,and the toxicity was tolerable.